Author: Zhang Hongtao (Zhang Hongtao), School of Medical Pathology and Experimental Research, Associate Professor of Medicine, University of Pennsylvania, USA.
1, Does the Israeli Covid-19 cure have a cure rate of over 95% in 3 to 5 days?
Israeli scientists recently announced that they have developed a “special drug for Covid-19, with no side effects, the cure rate exceeds 95% in 3 to 5 days”.
The above news is said to come from the account of the “Embassy of Israel in China”.
The account said in a tweet on Feb. 10, “Israel has achieved a major breakthrough: Our scientists have successfully developed a new drug against the SARS-CoV-2 virus and The cure was successful in the first phase of clinical trials conducted at Izirov Hospital in Tel Aviv for 29 out of 30 infected people, the cure rate exceeded 95%. “
After reading the tweet, anyone who observes will know that this is just the complete step of the Phase 1 clinical trial.
Over the past year, too many Covid-19 drugs have completed phase 1 clinical trials. If all are expected to be special therapies, hopefully as many as they will be.
The phase 3 clinical trial is still incomplete, and I dare not say that “has successfully developed a new drug to deal with Covid-19”, I can only say that the phase 1 clinical trial completed successfully.
2, Israel’s new drug “divine” to what extent?
I checked and found that a new Israeli drug in development, called EXO-C24, was an inhaler.
This drug is not an antiviral but a drug that regulates immune function and avoids “cytokine storms”. It actually uses a CD24 recombinant protein.
In the phase 1 clinical trial, 30 patients with moderate and severe Covd-19 infection were treated with inhalers once daily for five minutes each. 29 people recovered within 3-5 days after treatment, which is also the basis for the 95% cure rate.
It can be seen that at this stage 1, there was no control group in the study, so it was impossible to fully evaluate the effectiveness of the reagents. However, if a patient with moderate to severe Covid-19 infection can cure 95% within 3-5 days, the effect is still good.
Is this really possible?
We need to wait for the next phase 3 clinical trials to confirm. So what can they do if the phase 1 clinical trial is successful? They can continue to experiment.
As for “no side effects”, it was impossible to say from 30 people in the first round of testing. At most, they could only say “no obvious side effects”.
This is like saying “no side effects” after Covid-19 vaccine went through phase 1 trial.
In fact, there is a similar drug in phase 3 testing
The Israeli drug has only recently successfully completed the Phase 1 clinical trial, but there is a similar drug that has already been in the Phase 3 clinical trial and has preliminary results.
This is CD24Fc of OncoImmune Company.
CD24Fc is a recombinant fusion protein of the CD24 and Fc antibody structures, the purpose is to prolong the life of CD24 in the endogenous and improve the efficacy of drugs.
Of course, the Israeli medicine is different from the OncoImmune CD24Fc. The former is an inhaler, while the latter requires an injection.
In September of last year, the OncoImmune Company published an analysis of the interim efficacy of a phase 3 clinical trial that showed that after being treated with CD24Fc, Covid-19 infected patients recovered faster. are significant compared with control patients, and the risk of death or respiratory failure is reduced by more than 50%.
In the CD24Fc clinical trial, patients in the control and treatment groups also received conventional treatments, so the effects of the combination may also be compared, in particular:
The mean recovery time of patients treated with placebo and radixivir was 13 days, and mean recovery time of patients on CD24Fc and Radixivir was 6 days, shortened to 7 days;
The mean recovery time of patients treated with placebo and glucocorticoids was 15 days, and mean recovery time of patients treated with CD24Fc and glucocorticoids was 5 days, down 10 days;
How good were the results of this mid-stage study?
In fact, Merck & Co. (Merck, USA) told us:
On November 23, 2020, Merck announced the acquisition of OncoImmune Immunity Company and CD24Fc clinical development interest in a price tag of $ 425 million.
It is worth mentioning that OncoImmune was established in 2000 and headquartered in Rockville, Maryland, USA, the founders are two Chinese scientists, Dr. Liuyang (Liu Yang) and Dr. Dang. Judge (Zheng Pan).
4, What exactly does CD24 do?
CD24 is a cell surface protein that can bind to a “pattern recognition receptor” called Siglec10, which can regulate the activation of the innate immune system.
Specifically, CD24 after combining with Siglec10 can inhibit the activity of many immunogenic cytokines (such as TNF-α, IL-1β and IL-6), ie inhibiting the “immune cytokine storm”.
Images from OncoImmune’s website.
Currently, viral infection is no longer a major problem for patients who are seriously ill with COVID-19.
The main problem is the excessive immunity caused by a viral infection. This powerful immune system response initially kills the virus, but it will also cause damage to normal tissues and organs.
Faced with the SARS-CoV-2 virus, we must not only fight the virus, but also heal the wound. This is true for individuals, and in human society.
So, is CD24Fc a cure?
The current phase 3 trials are not yet fully completed, and we still need to wait for official results to be clear.
If it is indeed possible to reduce the risk of death or respiratory failure by 50% in critically and critically recent Covid-19 patients, then it can be said to be a special drug today!
The answer will be revealed soon.
* Translated from Health / Sohu
#bad #special #medicine #Israel